Drug
LY2940680 clinical trials
Also written LY2940680, taladegib and ENV-101.
- studies test it
- 12
- open now
- 1
- in phase 3
- 0
- first study started
- 2010
Keep track of what changes. Save the LY2940680 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2013 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 4 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
Eli Lilly and Company (6) · Endeavor Biomedicines, Inc. (5) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses LY2940680 is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy ParticipantsRecruitingPhase 1Endeavor Biomedicines, Inc.NCT07454291Written as taladegib
- A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsCompletedPhase 2Endeavor Biomedicines, Inc.NCT05199584Written as ENV-101 (taladegib)
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)Active, not recruitingPhase 2Endeavor Biomedicines, Inc.NCT06422884Written as ENV-101
- A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2Endeavor Biomedicines, Inc.NCT04968574Written as taladegib
- A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy SubjectsCompletedPhase 1Endeavor Biomedicines, Inc.NCT05817240Written as taladegib
- Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction CancerTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02530437Written as Taladegib
- A Study of LY2940680 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT01681186Written as LY2940680 Capsule(s) (Reference)
- A Study in Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01226485Written as Taladegib
- A Study of LY2940680 in Japanese Participants With Advanced CancersCompletedPhase 1Eli Lilly and CompanyNCT01919398Written as LY2940680
- A Study of LY2940680 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT01746745Written as [^14C]-LY2940680
- A Study of LY2940680 in Small Cell Lung CancerTerminatedPhase 1/2Eli Lilly and CompanyNCT01722292Written as LY2940680
- A Study of LY2940680 in Pediatric Medulloblastoma or RhabdomyosarcomaWithdrawnPhase 1Eli Lilly and CompanyNCT01697514Written as LY2940680
Given in every arm · 1 — LY2940680 is usual care beside what is tested
Codes
What other systems call LY2940680 · ClinicalTrials.gg INT006290
- MeSH (NLM) C581399LY2940680One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581399 | LY2940680 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.